Erlotinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer That Can Be Removed By Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00313560|
Recruitment Status : Completed
First Posted : April 12, 2006
Last Update Posted : April 6, 2016
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Drugs used in chemotherapy, such as capecitabine and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving erlotinib together with combination chemotherapy and radiation therapy after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This randomized phase II trial is studying how well giving erlotinib before and after surgery together with combination chemotherapy and radiation therapy works in treating patients with stage I or stage II pancreatic cancer that can be removed by surgery.
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer||Drug: erlotinib hydrochloride Other: placebo||Phase 2|
- Determine the pharmacodynamic (inhibition of epidermal growth factor receptor [EGFR] activation and signaling) effects of neoadjuvant erlotinib hydrochloride on tumor tissue of patients with resectable stage I or II pancreatic adenocarcinoma.
- Determine, preliminarily, antitumor activity (progression-free survival) of adjuvant erlotinib hydrochloride in combination with standard chemoradiotherapy comprising capecitabine, gemcitabine hydrochloride, and radiotherapy after surgical resection in these patients.
- Characterize the toxicity profile of adjuvant erlotinib hydrochloride in combination with standard chemoradiotherapy in these patients.
- Determine the pharmacodynamic (inhibition of EGFR activation and signaling) effects of erlotinib hydrochloride on normal tissue (skin and oral mucosa) of patients receiving erlotinib hydrochloride as adjuvant therapy.
- Characterize the pharmacokinetics of erlotinib hydrochloride (assessing both total and unbound levels) given in combination with capecitabine and evaluate the association of common allelic variants in candidate genes (EGFR, TS, DPD, MTHFR, and ORM1) with drug disposition and toxicity.
- Determine the relationships between pharmacodynamic effects and patient outcome.
- Assess the value of PET/CT scanning as a predictor of response to erlotinib hydrochloride treatment in patients with pancreatic cancer.
- Evaluate the benefit of fusing PET/CT scans together with the radiation treatment planning CT scan.
- Determine if the Active Breathing Coordinator (ABC) minimizes the effects of respiratory motion during radiation treatment and results in better radiation coverage of the tumor bed and adjacent lymph nodes.
OUTLINE: This is a randomized, placebo-controlled study.
Neoadjuvant therapy: Patients are randomized to 1 of 2 neoadjuvant treatment arms.
- Arm I: Patients receive oral erlotinib hydrochloride once a day for 3-5 days. Patients then proceed to surgery.
- Arm II: Patients receive oral placebo once a day for 3-5 days. Patients then proceed to surgery.
- Surgery: Patients undergo surgical resection. Patients then proceed to adjuvant therapy.
- Adjuvant therapy: Patients receive oral capecitabine twice a day and oral erlotinib hydrochloride once a day for 5½ weeks. Patients also undergo concurrent radiotherapy 5 days a week for 5½ weeks. Beginning 6 weeks later, patients receive gemcitabine hydrochloride IV on days 1, 8, and 15 and oral erlotinib hydrochloride once daily on days 1-28. Treatment with gemcitabine hydrochloride and erlotinib hydrochloride repeats every 28 days for 4 courses.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||52 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Phase II Study of Erlotinib (Tarceva) Combined With Chemoradiation and Adjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer|
|Study Start Date :||January 2006|
|Primary Completion Date :||December 2008|
Experimental: Arm I
Patients receive oral erlotinib hydrochloride once a day for 3-5 days. Patients then proceed to surgery.
Drug: erlotinib hydrochloride
Placebo Comparator: Arm II
Patients receive oral placebo once a day for 3-5 days. Patients then proceed to surgery.
- Pharmacodynamics of neoadjuvant erlotinib
- Antitumor activity of adjuvant therapy (erlotinib hydrochloride, capecitabine, gemcitabine hydrochloride, and radiotherapy) following surgical resection
- Toxicity profile of adjuvant therapy
- Pharmacodynamic effects of adjuvant erlotinib hydrochloride on normal tissue
- Pharmacokinetics of erlotinib hydrochloride and capecitabine
- Allelic variants in candidate genes (EGFR, TS, DPD, MTHFR, and ORM1) as related to drug disposition and toxicity
- Correlate pharmacodynamics and patient outcomes
- Predicted response by positron-emission tomography (PET)/CT scan
- Benefit of fusing PET/CT scans together with the radiotherapy planning CT scan
- Decreased respiratory motion during radiation treatment and better radiation coverage by using the Active Breathing Coordinator
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00313560
|United States, Maryland|
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|
|Baltimore, Maryland, United States, 21231-2410|
|Study Chair:||Joseph Herman, MD||Sidney Kimmel Comprehensive Cancer Center|